Market Spotlight:  Idiopathic Pulmonary Fibrosis

 Disease Overview

Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease in which scarring and thickening of the lung tissue occurs due to unknown causes. In turn, this fibrosis reduces the ability of alveoli to transport oxygen from the lungs to the bloodstream, and results in symptoms such as dyspnea, chronic dry cough, fatigue, and weight loss. While lung function and capacity steadily decline in most IPF patients, some experience a sudden, rapid increase in irreversible disease progression called acute exacerbation. The prognosis of patients with IPF remains poor as those who are ineligible for lung transplantation have few effective treatment options.

Market Snapshot

The size of the IPF market is set to expand significantly due to the growth of Esbriet and Ofev in the US.
Treatment of IPF is evolving as mounting evidence and revised international guidelines support clinical decision-making.

By 2035, Datamonitor Healthcare estimates that approximately 101,060 cases of IPF will be diagnosed annually in these markets. As IPF disproportionately affects the elderly, aging populations in these markets will be responsible for the largest increases in IPF.

Safety and efficacy of Esbriet and Ofev are comparable, but a few small advantages will help Esbriet remain the market-leading therapy.

The design of clinical trials continues to standardize as pipeline drugs seek to reverse disease progression.

Exclusive Sample Report @ https://www.reportsworldwide.com/enquiry?report_id=42616

Major TOC Market:

FORECAST: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)
EXECUTIVE SUMMARY
RECENT FORECAST UPDATES
MARKET DYNAMICS
FORECAST AND FUTURE TRENDS
MARKET DEFINITION AND METHODOLOGY
PRIMARY RESEARCH METHODOLOGY
BIBLIOGRAPHY
PRODUCT PROFILE: ESBRIET
PRODUCT PROFILE: OFEV
TREATMENT: IDIOPATHIC PULMONARY FIBROSIS (Published on 06 November 2017)
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS
EPIDEMIOLOGY: IDIOPATHIC PULMONARY FIBROSIS (Published on 10 February 2016)
EXECUTIVE SUMMARY
SOURCES AND METHODOLOGY
FORECAST.

CONTINUED……………………………

LIST OF FIGURES
Figure 1: Idiopathic pulmonary fibrosis – current and future market dynamics analysis
Figure 35: Datamonitor Healthcare’s drug assessment summary of pamrevlumab for idiopathic pulmonary fibrosis
Figure 3: Idiopathic pulmonary fibrosis drug sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 4: Total sales categorized by severity across the US, Japan, and five major EU markets, 2016–
Figure 5: Patient-based forecast methodology for idiopathic pulmonary fibrosis
Figure 6: Price sources and calculations, by country
Figure 7: Esbriet for idiopathic pulmonary fibrosis – SWOT analysis
Figure 8: Datamonitor Healthcare’s drug assessment summary of Esbriet for idiopathic pulmonary fibrosis.

CONTINUED……………………………

LIST OF TABLES
Table 1: Summary of drug classes and molecules included in Datamonitor Healthcare’s idiopathic pulmonary fibrosis patientbased forecast
Table 2: Exchange rates used for calculating prices
Table 3: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
Table 4: Esbriet drug profile
Table 5: Esbriet Phase III data in idiopathic pulmonary fibrosis
Table 6: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 7: Ofev drug profile
Table 8: Ofev pivotal trial data in idiopathic pulmonary fibrosis
Table 9: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 10: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
Table 11: Subtypes of idiopathic interstitial pneumonias
Table 12: Datamonitor Healthcare’s definition of idiopathic pulmonary fibrosis severity
Table 13: Estimated percentage of idiopathic pulmonary fibrosis patients in each severity who remain undiagnosed across the US, Japan, and five major EU markets
Table 14: Approved treatments available for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
Table 15: Off-label therapies used in the treatment of idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
Table 16: Non-pharmacological therapies used in the treatment of idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
Table 17: Pharmacological treatment regimens used in mild idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country.

CONTINUED……………………………

Ask to Expertise @ https://www.reportsworldwide.com/enquiry?report_id=42616

About US:

Reportsworldwide.com is a one stop shop for all market intelligence needs. Our database of market research reports provides in depth coverage of 12 top industry verticals worldwide. We help you meet your market intelligence needs by mapping it with our database of market research reports including.

Contact Us:

Email: sales@reportsworldwide.com

Phone: +1 (617) 398-1947